Neurotoxin Comparison: Botox vs Dysport vs Jeuveau vs Daxxify vs Xeomin

Botox (onabotulinumtoxinA, AbbVie) takes 3–7 days to show effect, peaks at 2 weeks, and lasts 12 weeks on average—though some patients report 16 weeks. Dysport (abobotulinumtoxinA, Galderma) kicks in faster: visible softening in 2–3 days, full effect by day 7, same 12-week duration. Xeomin (incobotulinumtoxinA, Merz) has no human serum albumin or gelatin excipients, which theoretically reduces antibody formation in repeat patients; onset mirrors Botox at 3–7 days, duration 12 weeks. Jeuveau (prabotulinumtoxinA, Evolus) is bioequivalent to Botox in onset and duration—3–7 days, 12 weeks—but positioned as the "millennial toxin" with aggressive rebate programs. Daxxify (abobotulinumtoxinA- avstmn, AbbVie, approved 2023) is the outlier: same onset as Dysport (2–3 days), but duration extends to 6 months in many patients, with some reporting 7 months. The trade-off is cost; Daxxify's per-unit price is roughly 2–3× Botox. Onset speed matters for patient satisfaction and retreat scheduling; duration drives loyalty and per-year revenue per patient.

The FDA doesn't publish official conversion ratios, but clinical practice and manufacturer guidance establish rough equivalencies. Botox and Xeomin are considered 1:1 in units—20 units Botox ≈ 20 units Xeomin for glabellar lines. Dysport is typically dosed at a 3:1 or 2.5:1 ratio to Botox, meaning 60 units Dysport ≈ 20 units Botox. This ratio exists because Dysport's formulation diffuses more readily; practitioners often use the higher unit count to justify a similar or slightly lower price point, banking on faster onset as the value prop. Jeuveau is 1:1 with Botox. Daxxify dosing is 1:1 with Dysport (so roughly 3:1 to Botox), but the extended duration means fewer treatments per year. A patient on 20 units Botox four times yearly (80 units/year) might need 60 units Daxxify twice yearly (120 units/year in absolute units, but only two appointments). The per-unit cost must be evaluated against annual patient revenue, not per-appointment revenue.

Botox wholesale cost varies by volume and rebate tier but typically ranges $10–$14 per unit for established practices; retail pricing is $12–$20 per unit depending on geography and market positioning. AbbVie's Alle loyalty program (formerly Allergan Rewards) now includes quarterly Botox rebates for qualifying growth, incentivizing volume commitments. Dysport wholesale is generally $8–$12 per unit; Galderma's rebate structure is less aggressive than AbbVie's but competitive. Xeomin wholesale runs $9–$13 per unit; Merz offers rebates but typically lower absolute dollars than Allergan. Jeuveau is the price leader: wholesale $6–$10 per unit, with Evolus Rewards offering volume-based rebates and quarterly bonuses. Daxxify wholesale is $25–$35 per unit—significantly higher—but the math improves when you factor in reduced treatment frequency. A patient paying $300 for 60 units Daxxify every 6 months ($600/year) may cost less per year than $400 for 20 units Botox four times yearly ($1,600/year), even at higher per-unit retail. Your margin per unit is lower on Daxxify, but margin per patient per year may be higher. Check your specific rebate tier with each manufacturer; Alle, Aspire (Galderma's program), and Evolus Rewards all require minimum quarterly purchases and offer tiered incentives.

Roughly 7–10% of patients develop neutralizing antibodies to botulinum toxin over time, rendering the product ineffective. Xeomin has a theoretical advantage here: the absence of complexing proteins may reduce immunogenicity, though clinical data is mixed. Some practices rotate Xeomin into repeat patients who've lost response to Botox, with anecdotal success. Dysport and Botox have similar immunogenicity profiles. Jeuveau and Daxxify are too new for long-term antibody data, but early reports suggest no unusual patterns. If you're seeing a patient plateau after 5+ years of Botox, switching to Xeomin or Dysport is a legitimate clinical move and a revenue recovery play. Stocking all five allows you to address this without losing the patient.

Botox remains the category leader by volume and brand recognition; most patients ask for it by name. Dysport has carved a niche among patients who value speed and those in competitive markets where practitioners promote the 2–3 day onset. Xeomin appeals to patients concerned about additives and those with prior antibody issues. Jeuveau has gained traction in price-sensitive demographics and practices that emphasize value; Evolus' direct-to-consumer marketing (social media, influencer partnerships) has built brand awareness among younger patients. Daxxify is still ramping; early adopters are patients willing to pay premium prices for 6-month duration and fewer appointments. Your mix should reflect your patient demographic. A high-end practice in Manhattan may stock primarily Botox and Daxxify; a value-focused medspa in a secondary market may lead with Jeuveau and Dysport. Offer choice, but guide based on clinical fit and your margin targets.

AbbVie (Botox, Daxxify) is the largest player; supply is reliable, rebate programs are complex but generous for high-volume practices. Watch their quarterly 8-K filings for changes to Alle terms. Galderma (Dysport) is stable; Aspire rebates are straightforward. Merz (Xeomin) is solid but smaller; rebates are modest. Evolus (Jeuveau) is the wild card: the company has posted positive EBITDA and raised guidance in recent quarters (Q2 2026), signaling operational stability, but it remains smaller and more price-aggressive. Evolus Rewards offers meaningful rebates, but monitor their financial health; smaller manufacturers can face supply disruptions or program changes. Diversify your sourcing across at least three manufacturers to hedge supply and rebate risk. Lock in volume commitments only if the rebate math is transparent and the manufacturer's financial footing is solid.

Price per unit, not per syringe or per vial. A 20-unit Botox treatment at $15/unit is $300; a 60-unit Dysport treatment at $8/unit is $480, but the patient sees "more units" and may perceive it as expensive. Educate your team on the unit-conversion story so they can explain why Dysport isn't cheaper—it's faster. For Daxxify, reframe as cost-per-year, not cost-per-visit: "$600 twice yearly is less than $1,600 four times yearly." Offer a tiered menu: "Botox for value, Dysport for speed, Daxxify for longevity, Xeomin if you've had prior reactions." This positions you as clinically sophisticated and gives patients agency. Your cost per unit is locked in by rebate tier; your retail price is your lever. Don't race to the bottom on price—you'll erode margin and train patients to shop on cost alone. Compete on outcomes, speed, and convenience instead.

Stock Botox as your anchor (brand recognition, rebate volume), Dysport or Jeuveau for speed and price sensitivity, Xeomin for antibody-resistant patients, and Daxxify for high-value, low-frequency patients. Understand your per-unit cost under each rebate program, price per unit (not per vial), and track per-patient annual revenue, not per-visit revenue. Daxxify's higher per-unit cost is offset by fewer treatments; Jeuveau's lower cost is offset by lower margins. The real profit is in patient lifetime value and repeat frequency, not unit volume.